Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

NCT03936933 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class

Stopped Low recruitment rate and number of subjects is less than required after 3 years.

Conditions

Interventions

Sponsor

Eurofarma Laboratorios S.A.